Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[mlkrborn]

Ligand Pharma announced that it has entered into platform Captisol license and supply agreements with Eli Lilly (LLY) in undisclosed therapeutic areas (LGND) 12.00 : Co announced that it has entered into platform Captisol license and supply agreements with Eli Lilly (LLY) in undisclosed therapeutic areas. During the collaboration, Lilly will be permitted to nominate an unlimited number of drug candidates from its internal pipeline for Captisol formulation. Ligand will provide clinical supplies of Captisol, and may ultimately supply commercial quantities of Captisol to Lilly if a product should be successfully commercialized. Under the terms of the agreement, Ligand will receive a $1 million upfront payment. Other financial terms of the deal were not disclosed.